

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1. (Original) A substantially pure polypeptide selected from the group consisting of:
  - (a) a polypeptide comprising the amino acid sequence of SEQ ID NO: 4 or 6;
  - (b) a polypeptide that comprises the amino acid sequence of SEQ ID NO: 4 or 6 in which one or more amino acids are substituted, deleted, inserted, and/or added and that has a biological activity equivalent to a protein consisting of the amino acid sequence of SEQ ID NO: 4 or 6; and
  - (c) a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 3 or 5, wherein the polypeptide has a biological activity equivalent to a polypeptide consisting of the amino acid sequence of any one of SEQ ID NO: 4 or 6.
- 2-5. (Cancelled)
6. (Previously Presented) A method for producing the polypeptide of claim 1-or 2, said method comprising the steps of:
  - (a) culturing a host cell comprising:
    - (1) a polynucleotide encoding the polypeptide; or
    - (2) a vector comprising the polynucleotide encoding the polypeptide;
  - (b) allowing the host cell to express the polypeptide; and
  - (c) collecting the expressed polypeptide.
- 7-30. (Cancelled)

31. (Original) A pharmaceutical composition for treating or preventing a cancer, said composition comprising a pharmaceutically effective amount of polypeptide selected from the group of (a)-(c), or a polynucleotide encoding the polypeptide:

- (a) a polypeptide comprising the amino acid sequence of SEQ ID NO: 2, 4 or 6, or fragment thereof;
- (b) a polypeptide that comprises the amino acid sequence of SEQ ID NO: 2, 4 or 6 in which one or more amino acids are substituted, deleted, inserted and/or added and that has a biological activity equivalent to a protein consisting of the amino acid sequence of SEQ ID NO: 2, 4 or 6, or fragment thereof;
- (c) a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 1, 3 or 5, wherein the polypeptide has a biological activity equivalent to a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2, 4 or 6, or fragment thereof

as an active ingredient, and a pharmaceutically acceptable carrier.

32. (Original) The pharmaceutical composition of claim 31, wherein the polynucleotide is incorporated in an expression vector.

33. (Cancelled)